Myeloproliferative

Indeed, as the report said, doctors test for the JAK2 variant to confirm cases of these diseases, called myeloproliferative disorders. ❋ Unknown (2012)

CYT387 is a potent inhibitor of the kinase enzymes JAK1 and JAK2, which have been implicated in a family of hematological conditions known as myeloproliferative neoplasms, including myelofibrosis. ❋ Unknown (2010)

CYT387 is an inhibitor of the kinase enzymes JAK1 and JAK2, which have been implicated in a family of hematological conditions known as myeloproliferative neoplasms, including myelofibrosis, and as well in numerous disorders including indications in hematology, oncology and inflammatory diseases. ❋ Unknown (2010)

That's what happens in a particular class of blood cell disorders called myeloproliferative neoplasms, or MPNs. ❋ Unknown (2010)

The study, published in the journal Nature Genetics, has shown that susceptibility to a series of blood cancers, known as myeloproliferative disorders (MPDs), is linked to a particular area of the patient's DNA, which is prone to developing mutations. ❋ Unknown (2009)

YM BioSciences understands that the dose-escalation Phase I/II study by Cytopia is investigating the safety and tolerability of CYT387 administered as a daily oral capsule dose in 30-60 patients with myelofibrosis, a disorder within a family of hematological conditions known as myeloproliferative neoplasms (MPN) and that the study will also allow preliminary assessment of the compound's activity in these patients including its effect on spleen size, hematological symptoms, quality-of-life and markers of aberrant JAK2 activity in blood.

The Clinical Haematology Department of the institute, in collaboration with the Department of Immunology, has distinguished itself by starting detection of JAK-2 Mutations in patients with myeloproliferative disorders. ❋ Unknown (2009)

This expansion led by 6 to 12 months post-transplantation to the development of a myeloproliferative disease, which can evolve to leukemia. ❋ Unknown (2009)

CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers.

In addition to Sanders, the Indiana firefighter, I spoke with Bob Rosen, chairman of the MPN Research Foundation, a Chicago-based advocacy group for people with myeloproliferative disorders, and he had a surprise for me. ❋ Unknown (2012)